CTMX ▲ +2.7% - CytomX Therapeutics, Inc.
$CTMX - CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
27-AUG-2026 08:00 AM ET
Share this post
More filings for $CTMX
CTMX ▼ -0.6% - CytomX Therapeutics, Inc.Sep 1, 2026CTMX - CytomX Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CTMX - CytomX Therapeutics, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026$CTMX SEC Filing Update (03-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 3, 2026$CTMX SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 27, 2026
View full $CTMX filing history →💬 Comments
Loading comments…
Leave a comment